piperine and Brain-Neoplasms

piperine has been researched along with Brain-Neoplasms* in 2 studies

Other Studies

2 other study(ies) available for piperine and Brain-Neoplasms

ArticleYear
Survivin Inhibition by Piperine Sensitizes Glioblastoma Cancer Stem Cells and Leads to Better Drug Response.
    International journal of molecular sciences, 2022, Jul-09, Volume: 23, Issue:14

    Glioblastoma multiforme (GBM) cancer stem cells (GSCs) are one of the strongest contributing factors to treatment resistance in GBM. Identification of biomarkers capable of directly affecting these cells within the bulk tumor is a major challenge associated with the development of new targeting strategies. In this study, we focus on understanding the potential of the multifunctional extraordinaire survivin as a biomarker for GSCs. We analyzed the expression profiles of this gene using various publicly available datasets to understand its importance in stemness and other cancer processes. The findings from these studies were further validated using human GSCs isolated from a GBM cell line. In these GSCs, survivin was inhibited using the dietary phytochemical piperine (PIP) and the subsequent effects on stemness, cancer processes and Temozolomide were investigated. In silico analysis identified survivin to be one of the most significant differentially regulated gene in GSCs, in comparison to common stemness markers. Further validation studies on the isolated GSCs showed the importance of survivin in stemness, cancer progression and therapy resistance. Taken together, our study identifies survivin as a more consistent GSC marker and also suggests the possibility of using survivin inhibitors along with standard of care drugs for better therapeutic outcomes.

    Topics: Alkaloids; Benzodioxoles; Brain Neoplasms; Cell Line, Tumor; Cytochrome P-450 Enzyme Inhibitors; Glioblastoma; Humans; Neoplastic Stem Cells; Piperidines; Polyunsaturated Alkamides; Survivin

2022
Development of core-shell nanocarrier system for augmenting piperine cytotoxic activity against human brain cancer cell line.
    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2018, Jun-15, Volume: 118

    Brain tumor has a low prognosis with only 15% survival rate (5 years after diagnosis). Many of the current therapeutics have limited activity due to their inability to cross the blood brain barrier which retards drug accumulation in tumor site and causes drug resistance. Piperine, a phytochemical drug with poor solubility, could be an alternative to current therapeutics after evading its solubility and permeability limitations. Piperine micellization was optimized to improve drug solubility. Positively charged trimethyl-chitosan was synthesized then electrostatically adsorbed onto piperine nanomicelles forming core-shell nanoparticles. Physicochemical and morphological characterizations, and in-vitro release were performed. Cytotoxicity on human brain cancer cell line (Hs683) was evaluated using IC50 determination, cell cycle arrest analysis, apoptosis and enzyme-linked immunosorbent assay. Optimum piperine-loaded core-shell nanoparticles were successfully fabricated with double-phase release model. Significant improvement in cytotoxicity than free drug was noted with increasing in G2/M-phase and pre-GI-phase population, apoptotic/necrotic rates and inhibition of CDK2a.

    Topics: Alkaloids; Antineoplastic Agents; Apoptosis; Benzodioxoles; Brain Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Survival; Chitosan; Drug Carriers; Drug Liberation; Humans; Inhibitory Concentration 50; Micelles; Nanoparticles; Piperidines; Polyunsaturated Alkamides; Solubility

2018